Aldeyra Therapeutics, Inc.
ALDX
$1.71
-$0.05-2.84%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.14M | 2.36M | 2.57M | 1.66M | 3.00M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.55M | 6.67M | 8.00M | 10.17M | 10.43M |
| Operating Income | -3.55M | -6.67M | -8.00M | -10.17M | -10.43M |
| Income Before Tax | -3.45M | -6.46M | -7.69M | -9.77M | -9.93M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.45M | -6.46M | -7.69M | -9.77M | -9.93M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.45M | -6.46M | -7.69M | -9.77M | -9.93M |
| EBIT | -3.55M | -6.67M | -8.00M | -10.17M | -10.43M |
| EBITDA | -3.48M | -6.60M | -7.94M | -10.11M | -10.37M |
| EPS Basic | -0.06 | -0.11 | -0.13 | -0.16 | -0.17 |
| Normalized Basic EPS | -0.04 | -0.07 | -0.08 | -0.10 | -0.10 |
| EPS Diluted | -0.06 | -0.11 | -0.13 | -0.16 | -0.17 |
| Normalized Diluted EPS | -0.04 | -0.07 | -0.08 | -0.10 | -0.10 |
| Average Basic Shares Outstanding | 60.32M | 60.16M | 60.13M | 60.05M | 59.89M |
| Average Diluted Shares Outstanding | 60.32M | 60.16M | 60.13M | 60.05M | 59.89M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |